Oncology News | pharmaphorum

News

ASH: Servier's Tibsovo poised for first-line used in AML

Servier has revealed the full data from its phase 3 trial of Tibsovo as a first-line treatment for acute myeloid leukaemia that it

News

Roche builds case for TIGIT combo in untreated lung cancer

Roche's closely-watched combination of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq has shown long-term efficacy in an ongoing trial in lung cancer, adding to the evidence

News

AZ, Daiichi take aim at Gilead in triple-negative breast can...

AstraZeneca and Daiichi Sankyo have reported new data with their antibody-drug conjugate for triple-negative breast cancer (TNBC), as they build a case to challenge Gilead's already-markete

News

Henlius claims win for PD-1 drug in small cell lung cancer

China's Shanghai Henlius Biotech says its experimental PD-1 inhibitor serplulimab has extended survival when added to chemotherapy in a phase 3 trial as first-line therapy for extensive sta

News

Merck claims another adjuvant okay from FDA for Keytruda

Merck & Co's strategy of pushing Keytruda earlier in the treatment pathway for cancers has secured anther victory, after the FDA approved the immunotherapy for adjuvant treatment of ski

News

Trial closes gap between Bayer's Nubeqa and rivals in prosta...

Bayer's Nubeqa is making headway as a treatment for castration-resistant prostate cancer (CRPC), but could be on track to expand its eligible patient population thanks to new phase 3 data.<

ASH: Servier's Tibsovo poised for first-line used in AML

Roche builds case for TIGIT combo in untreated lung cancer

AZ, Daiichi take aim at Gilead in triple-negative breast can...

Henlius claims win for PD-1 drug in small cell lung cancer

Merck claims another adjuvant okay from FDA for Keytruda

Trial closes gap between Bayer's Nubeqa and rivals in prosta...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks